Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimalarials | 2 | 2024 | 63 | 1.010 |
Why?
|
| Drug Synergism | 2 | 2024 | 189 | 1.010 |
Why?
|
| Plasmodium falciparum | 2 | 2024 | 146 | 0.950 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 94 | 0.890 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 11 | 0.890 |
Why?
|
| Hospital Mortality | 4 | 2020 | 206 | 0.870 |
Why?
|
| Drug Combinations | 1 | 2024 | 102 | 0.820 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 406 | 0.780 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 188 | 0.680 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 22 | 0.650 |
Why?
|
| Mitral Valve | 1 | 2020 | 37 | 0.650 |
Why?
|
| Computational Biology | 4 | 2023 | 324 | 0.620 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 50 | 0.610 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 71 | 0.430 |
Why?
|
| Reference Values | 2 | 2024 | 207 | 0.420 |
Why?
|
| Saccharomyces cerevisiae Proteins | 3 | 2021 | 110 | 0.410 |
Why?
|
| Biomedical Research | 3 | 2023 | 467 | 0.410 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2021 | 199 | 0.390 |
Why?
|
| Humans | 21 | 2024 | 42163 | 0.340 |
Why?
|
| Risk Assessment | 3 | 2019 | 845 | 0.280 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1586 | 0.250 |
Why?
|
| Aged | 6 | 2024 | 7982 | 0.230 |
Why?
|
| Proteomics | 2 | 2024 | 363 | 0.230 |
Why?
|
| Aryldialkylphosphatase | 1 | 2024 | 14 | 0.220 |
Why?
|
| Nucleus Accumbens | 1 | 2025 | 99 | 0.220 |
Why?
|
| Hydrazones | 1 | 2024 | 11 | 0.220 |
Why?
|
| Extinction, Psychological | 1 | 2025 | 103 | 0.210 |
Why?
|
| Plasmodium berghei | 1 | 2024 | 35 | 0.210 |
Why?
|
| United States | 5 | 2022 | 5072 | 0.210 |
Why?
|
| Bayes Theorem | 2 | 2021 | 121 | 0.200 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 233 | 0.200 |
Why?
|
| Cannabinoids | 1 | 2024 | 67 | 0.200 |
Why?
|
| Female | 11 | 2024 | 24018 | 0.200 |
Why?
|
| Ethanol | 1 | 2025 | 221 | 0.200 |
Why?
|
| Malaria, Falciparum | 1 | 2024 | 91 | 0.190 |
Why?
|
| Fear | 1 | 2025 | 271 | 0.190 |
Why?
|
| Puerto Rico | 2 | 2024 | 1376 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 860 | 0.190 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 708 | 0.180 |
Why?
|
| SELEX Aptamer Technique | 1 | 2021 | 16 | 0.180 |
Why?
|
| Cisplatin | 1 | 2022 | 91 | 0.180 |
Why?
|
| Age Factors | 1 | 2024 | 1139 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2019 | 336 | 0.170 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 51 | 0.170 |
Why?
|
| RNA, Messenger | 1 | 2025 | 1265 | 0.170 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 146 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 158 | 0.160 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2021 | 59 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 729 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 112 | 0.160 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2019 | 13 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 290 | 0.150 |
Why?
|
| Geography | 1 | 2019 | 107 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 33 | 0.150 |
Why?
|
| ras Proteins | 1 | 2019 | 54 | 0.150 |
Why?
|
| Burns | 1 | 2018 | 10 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 2803 | 0.140 |
Why?
|
| Platelet Aggregation | 1 | 2018 | 21 | 0.140 |
Why?
|
| Software | 2 | 2023 | 234 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 438 | 0.140 |
Why?
|
| HIV-1 | 1 | 2024 | 747 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 70 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 201 | 0.140 |
Why?
|
| Wound Healing | 1 | 2018 | 82 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2019 | 169 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 230 | 0.130 |
Why?
|
| Skin | 1 | 2018 | 185 | 0.130 |
Why?
|
| Middle Aged | 4 | 2024 | 11819 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 301 | 0.120 |
Why?
|
| Algorithms | 2 | 2021 | 508 | 0.120 |
Why?
|
| Male | 8 | 2025 | 22779 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2019 | 362 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 933 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2019 | 548 | 0.110 |
Why?
|
| Risk Factors | 2 | 2019 | 3942 | 0.110 |
Why?
|
| Nucleotides | 2 | 2024 | 37 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 573 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 979 | 0.100 |
Why?
|
| Adult | 3 | 2024 | 13458 | 0.100 |
Why?
|
| Haplotypes | 2 | 2024 | 197 | 0.090 |
Why?
|
| Placenta | 2 | 2022 | 113 | 0.090 |
Why?
|
| HIV Infections | 1 | 2024 | 2535 | 0.080 |
Why?
|
| Minority Groups | 2 | 2022 | 663 | 0.070 |
Why?
|
| Mice | 3 | 2025 | 6490 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 1737 | 0.060 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2025 | 50 | 0.060 |
Why?
|
| Plasmodium cynomolgi | 1 | 2024 | 4 | 0.050 |
Why?
|
| Plasmodium vivax | 1 | 2024 | 8 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2024 | 62 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 77 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2024 | 92 | 0.050 |
Why?
|
| Exocytosis | 1 | 2024 | 49 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2024 | 75 | 0.050 |
Why?
|
| Lysosomes | 1 | 2024 | 88 | 0.050 |
Why?
|
| Writing | 1 | 2023 | 41 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2023 | 81 | 0.050 |
Why?
|
| Malaria | 1 | 2024 | 90 | 0.050 |
Why?
|
| Cystatin B | 1 | 2022 | 11 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 106 | 0.050 |
Why?
|
| Minority Health | 1 | 2022 | 96 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 105 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2022 | 42 | 0.050 |
Why?
|
| Language | 1 | 2023 | 181 | 0.050 |
Why?
|
| Decision Trees | 1 | 2021 | 22 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2021 | 24 | 0.040 |
Why?
|
| Gene Library | 1 | 2021 | 60 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 16695 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 21 | 0.040 |
Why?
|
| Research Personnel | 1 | 2022 | 191 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2022 | 188 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 421 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2024 | 355 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 4936 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2021 | 78 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 366 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 64 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 90 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 129 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 661 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 150 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1804 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 387 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 173 | 0.040 |
Why?
|
| Macrophages | 1 | 2024 | 515 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 928 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 28 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 850 | 0.040 |
Why?
|
| Mutation | 1 | 2024 | 1169 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 102 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 8 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1001 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 78 | 0.040 |
Why?
|
| Clone Cells | 1 | 2018 | 50 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 48 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 232 | 0.030 |
Why?
|
| Immunization | 1 | 2018 | 93 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 128 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2024 | 990 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1076 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 722 | 0.030 |
Why?
|
| Rabbits | 1 | 2018 | 292 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 231 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2018 | 80 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 729 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 253 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 683 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2018 | 884 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1420 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1188 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 875 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 357 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 692 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 2598 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1597 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3077 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 1848 | 0.030 |
Why?
|
| Child | 1 | 2019 | 3381 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5950 | 0.020 |
Why?
|